Silence Therapeutics plc (ADR)
General ticker "SLN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $256.8M (TTM average)
Silence Therapeutics plc (ADR) follows the US Stock Market performance with the rate: 39.7%.
Estimated limits based on current volatility of 5.0%: low 6.13$, high 6.78$
Factors to consider:
- Total employees count: 116 as of 2024
- Top business risk factors: Third-party risks, Regulatory and compliance, Cybersecurity threats, Manufacturing disruptions, Strategic risks and growth management
Short-term SLN quotes
Long-term SLN plot
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | £21.66MM | £25.38MM | £43.26MM |
| Operating Expenses | £82.69MM | £74.98MM | £106.58MM |
| Operating Income | £-61.04MM | £-49.60MM | £-63.32MM |
| Non-Operating Income | £11.39MM | £-0.71MM | £18.86MM |
| Interest Expense | £0.00MM | £0.03MM | £0.00MM |
| R&D Expense | £43.55MM | £44.02MM | £67.88MM |
| Income(Loss) | £-49.65MM | £-50.31MM | £-44.46MM |
| Taxes | £0.69MM | £0.00MM | £0.84MM |
| Profit(Loss)* | £-50.33MM | £-43.27MM | £-54.43MM |
| Stockholders Equity | £22.07MM | £21.99MM | £134.02MM |
| Assets | £107.50MM | £119.45MM | £202.63MM |
| Operating Cash Flow | £-57.04MM | £-39.35MM | £-67.64MM |
| Capital expenditure | £0.55MM | £0.04MM | £0.21MM |
| Investing Cash Flow | £-20.50MM | £16.43MM | £-21.97MM |
| Financing Cash Flow | £52.58MM | £25.16MM | £142.09MM |
| Earnings Per Share** | £-4.69 | £-3.50 | £-3.53 |
| Ordinary share to ADR | 0.33x | 0.33x | 0.33x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.